首页 | 本学科首页   官方微博 | 高级检索  
   检索      

缬沙坦对高血压合并肾小球肾炎患者Scr和GFR水平的影响
引用本文:华佳,王凉,张悦,张秋花,李深.缬沙坦对高血压合并肾小球肾炎患者Scr和GFR水平的影响[J].现代生物医学进展,2014,14(36):7070-7072.
作者姓名:华佳  王凉  张悦  张秋花  李深
作者单位:南京医科大学附属无锡市人民医院肾内科;北京大学第一医院肾内科
基金项目:国家自然科学基金重点项目(30330710)
摘    要:目的:探讨缬沙坦治疗高血压并肾小球肾炎临床疗效及对Scr(血清肌酐)、GFR(肾小球滤过率)水平变化的影响及临床意义。方法:选取我院收治的126例高血压合并肾小球肾炎患者为研究对象,随机分成A、B两组,各63例。A组给予低剂量(80mg/d)缬沙坦,B组给予高剂量(160 mg/d)缬沙坦。记录两组患者治疗前后SBP,Scr,GFR等临床指标变化情况及不良反应。结果:治疗前两组各项指标对比无明显差异(P0.05);治疗后,A,B两组SBP均较治疗前显著下降(P0.05);A组Scr呈升高趋势(P0.05),B组Scr呈轻微下降趋势(P0.05);A组、B组GFR变化不明显(P0.05)。A组不良反应率为4.76%,B组为9.52%,差异不显著(P0.05)。结论:对高血压合并肾小球肾炎患者给予高剂量缬沙坦,降压效果及耐受性好,毒副作用低,患者血清肌酐及肾小球虑过率水平无明显变化,值得临床推广。

关 键 词:缬沙坦  高血压  肾小球肾炎  Scr  GFR

Effect of Valsartan on the Level of Scr and GFR in Patients of High Blood Pressure with Glomerular Nephritis
HUA JIA,WANG LIAng,ZHANG Yue,ZHANG Qiu-hu,LI Shen.Effect of Valsartan on the Level of Scr and GFR in Patients of High Blood Pressure with Glomerular Nephritis[J].Progress in Modern Biomedicine,2014,14(36):7070-7072.
Authors:HUA JIA  WANG LIAng  ZHANG Yue  ZHANG Qiu-hu  LI Shen
Institution:HUA Jia;WANG Liang;ZHANG Yue;ZHANG Qiu-hua;LI Shen;Department of Nephrology, Wuxi People’s Hospital, the Affiliated Hospital of Nanjing Medical University;Department of Nephrology, the First Hospital of Peking University;
Abstract:Objective:To explore the clinical curative effect of valsartan in pateients of high blood pressure with glomerular nephritis and its effects on the level change of Scr and GFR.Methods:126 cases of hypertension with glomerularnephritisin our hospital were selected as the research objects, which were randomly divided into A, B groups with number table method, each group with 63 cases, under valsartantherapy, in which group A was given low doses (80mg/d) and group B was given high doses (160mg/d). The change of the two groups before and after treatment of patients with various clinical indicators was recorded, and the adverse reaction was observed.Results:Before the treatment, no difference between the two groups of indicators before treatment (P>0.05). After treatment of valsartan, SBP in the control group and observation group significantly decreased than before treatment (P<0.05). Scr in group A showed an increase trend (P<0.05), while in group B, Scr A slight declined (P>0.05). No significant change of GFR was detected in group A and groupB (P>0.05). Adverse reaction rate of group A was 4.76%, while it was 9.52%in group B, without significant difference between them(P>0.05).Conclusion:High dose of valsartanin patients with hypertension combined glomerulonephritis has antihypertensive effect and good tolerance, low toxic and side effect, and the patients'' serumcreatinine and glomerular rate has no obvious change after drug, so it is worthy of clinical popularization and application to alleviate the illness.
Keywords:Valsartan  High blood pressure  Glomerulonephritis  Scr  GFR
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号